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Case Report

A 19-year-old man with no past medical history presented to
the ER with a sore throat, cough, and pleuritic chest pain. The
patient had been well until 1 month before admission, when
he developed a sore throat and felt ill. He presented to the
emergency department twice for these symptoms. On the first
visit, the patient had a positive rapid strep test. He was diagnosed
with strep throat and treated with penicillin IM. However, his
sore throat persisted. Five days before admission, the patient
developed a non-productive cough. One day prior to admission
he developed severe right sided chest pain that was throbbing,
pleuritic, and radiated to his right shoulder. The pain, which
was initially relieved by sitting forward and with Ibuprofen,
continued to worsen, prompting the patient’s mother to bring
him back to be re-evaluated.
Upon presentation, the patient denied shortness of breath, fevers,
or chills. He had no personal history of prenatal or childhood
disease, and denied family history of early heart disease, lung
disease, cancer or bleeding disorders. He denied tobacco,
alcohol, or illicit drug use. He reported being heterosexual with
4-5 lifetime sexual partners, and one new partner in the prior
two months.
On examination, the patient was a well nourished, well
developed, young African American man in moderate distress.
The blood pressure was 117/57, heart rate 66, respiratory
rate 16, oxygen saturation 98% on 2 L nasal cannula and
temperature 37.5ºC. The physical exam was remarkable only
for slight pharyngeal erythema and enlarged, non-purulent
tonsils. His heart was without murmurs, rubs, or gallops. His
lungs were clear to auscultation bilaterally. Initial labwork
was unremarkable, with a normal white blood cell count. A
chest radiograph revealed findings in the right lower lobe
concerning for subsegmental atelectasis versus consolidation.
Electrocardiogram demonstrated an incomplete right bundle
branch block. A thoracic CT demonstrated a large right lower
lobe pulmonary embolism with an associated area of pulmonary
infarction.
Given the finding of the patient’s pulmonary embolism, our
top three differential diagnoses were a primary underlying
hypercoagulable state, an infection predisposing the patient to a
hypercoaguable state, or an underlying malignancy. The patient
was admitted to the hospital, blood work was drawn, and he
was started on Warfarin with an Enoxaparin bridge. During his
work up, the patient was found to have elevated antistreptolysin
O titers, consistent with a prior streptococcus infection. Blood
cultures were negative. In addition, HIV, HSV, gonorrhea,
chlamydia, group A strep, and H1N1 PCR were all negative.
CT of the abdomen and pelvis and testicular ultrasound were

normal, without any signs of malignancy. A rheumatologic
workup, including an anti-nuclear antibody and anti-neutrophil
cytoplasmic antibody were negative. A hypercoagulable work up
was sent prior to initiation of anticoagulation therapy. Protein
C, protein S, factor V leiden, antithrombin III, and anticardiolipin antibodies were normal. Eventually, after the patient
had been discharged, his lupus anticoagulant levels returned as
abnormally elevated. The patient was diagnosed with primary
antiphospholipid syndrome by his primary care doctor and was
informed he would require lifelong anticoagulation.

Discussion

Primary antiphospholipid syndrome is an auto-immune disease
typically discovered when a patient has vascular thromboses or
pregnancy complications in the presence of elevated anticardiolipin antibodies or lupus anticoagulant antibodies. Primary
antiphospholipid syndrome can be diagnosed in the absence of
broader auto-reactive antibody production, i.e. lupus. Detection
of the auto-immune antibodies must be found on two separate
occasions more than six weeks apart.
Of the laboratory criteria, anticardiolipin antibodies are more
sensitive while the lupus anticoagulant antibodies are more
specific. Lupus anticoagulant antibodies were originally found in
lupus patients who had a prolonged activated partial thromboplastin time (aPTT). While patients with the lupus anticoagulant
had prolonged in vitro coagulation studies, in vivo they were
hyper-coaguable. Thus, these patients had high PTT or INR
on blood work, in combination with a paradoxical tendency to
clot in their body. This paradox is due to the fact that, in vitro,
the lupus anticoagulant antibody binds to critical phopholipids
and prevents them from activating factor X and prothrombin.
In vivo, however, the antiphospholipid antibody binds to a
multitude of targets that result in a hyper-coaguable state.
The lupus anticoagulant antibody has many significant targets
within the body. The most clinically important in vivo target
is β 2-glycoprotien. 2 Many patients have circulating lupus
anticoagulant antibodies that target phospholipids only, and
do not have clinically significant thrombosis. However, when
the antibodies target both phospholipids and β2-glycoprotien
I, the patients become much more likely to have a thrombus
that causes symptoms. Antiphospholipid antibodies also
promote coagulation by enhancing activation and aggregation
of platelets, activation and expression of adhesion molecules on
endothelium, and activation of the coagulation cascade.
Infection can be an inciting factor for a thrombotic event in
a patient with a circulating, but clinically silent, antiphospholipid antibody. Many different pathogens are cited, including
HIV, HCV, VZV, H influenza, Streptococcus species, and
Staphylococcus aureus. Common systems infected prior to
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thrombosis include skin, pulmonary, urinary, and upper
respiratory tract. 4 Some investigators propose a “two hit”
hypothesis in which patients with underlying antiphospholipid
antibodies receive a second hit when a pathogenic epitope is a
molecular mimic of β2-glycoprotein I or when an inflammatory
cascade is activated by toll-like receptors on phagocytes of the
innate immune system. It is possible this happened to our
patient: his previously silent circulating antibodies were activated
by an upper respiratory streptococcus infection, causing an
inflammatory cascade that resulted in a thrombotic event.

Our patient did not have catastrophic antiphospholipid
syndrome, and is currently doing well on oral anticoagulation.

Treatment for patients with primary antiphospholipid syndrome
centers on anticoagulation therapy. An INR of 2-3 (maintained
by oral warfarin) has been shown to reduce the probability of
recurrent thrombosis. In catastrophic cases where life threatening
thromboses affect multiple organs and cause microvascular
disease, treatment includes high dose steroids, intravenous
immunoglobulin, cyclophosphamide, or plasmapharesis.
Treatment in a hemodynamically compromised patient with
pulmonary embolism can also include embolectomy. For
prevention of late term pregnancy loss related to primary
anti-phospholipid syndrome, low dose aspirin and subcutaneous
prophylactic heparin have been shown to prevent complications.
For patients refractory to anti-coagulation, long term immunomodulating agents should be added.

3) I nfection can prompt a circulating but clinically silent
antiphospholipid antibody to cause a thrombotic event.
Exact mechanism of this is unknown.
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Take home points:

1) P
 rimary antiphospholipid syndrome is vascular thromboses
or pregnancy complications and anticardiolipin antibodies
or lupus anticoagulant antibodies.
2) A
 nticardiolipin antibodies are more sensitive while lupus
anticoagulant is more specific for diagnosing antiphospholipid syndrome.
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